Literature DB >> 10767056

Effects of NADH on dopamine release in rat striatum.

S M Pearl1, M D Antion, G D Stanwood, J D Jaumotte, G Kapatos, M J Zigmond.   

Abstract

Nicotinamide adenine dinucleotide (NADH) may be utilized for the synthesis and regeneration of tetrahydrobiopterin (BH(4)), which in turn is an essential cofactor for tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine (DA). NADH has been reported to relieve some of the symptoms of Parkinson's disease, presumably by altering dopaminergic function. The present study examines the efficacy of NADH in influencing DA activity in the rat striatum. In striatal slices, NADH (350 microM) significantly increased basal DA and DOPAC efflux and caused a 2-fold increase in the DA overflow evoked by high KCl (25 mM). Tissue levels of BH(4), basal BH(4) efflux, and KCl-evoked BH(4) overflow were unaffected by NADH, as was [(3)H]DA uptake into striatal synaptosomes. In contrast to the effects of NADH on DA function in vitro, no effects were observed when NADH was administered systemically. NADH (10 or 100 mg/kg, s.c.) did not influence the tissue content of DA, 5-HT, or their metabolites in the midbrain or striatum, nor did it alter DA extracellular concentrations. These results indicate that NADH can increase DA release from striatal slices, although we are as yet unable to detect this effect in vivo. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767056     DOI: 10.1002/(SICI)1098-2396(200005)36:2<95::AID-SYN2>3.0.CO;2-U

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  3 in total

1.  Niacin metabolism and Parkinson's disease.

Authors:  Tetsuhito Fukushima
Journal:  Environ Health Prev Med       Date:  2005-01       Impact factor: 3.674

2.  NADH supplementation decreases pinacidil-primed I K ATP in ventricular cardiomyocytes by increasing intracellular ATP.

Authors:  Brigitte Pelzmann; Seth Hallström; Peter Schaffer; Petra Lang; Karl Nadlinger; George D Birkmayer; Karoline Vrecko; Gilbert Reibnegger; Bernd Koidl
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

3.  Upregulation of GPR109A in Parkinson's disease.

Authors:  Chandramohan Wakade; Raymond Chong; Eric Bradley; Bobby Thomas; John Morgan
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.